Compare Nano Dimension Ltd - ADR (NNDM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs State Street SPDR S&P Biotech ETF — how do they compare? Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M), while State Street SPDR S&P Biotech ETF trades at $153.72 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 30.8× Nano Dimension Ltd - ADR's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nano Dimension Ltd - ADR for 43 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NNDM | XBI | |
|---|---|---|
Market Cap | $328.52M | $10.11B |
Volume | 1,160,945 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $2.14 | $169.55 |
52-Week Low | $1.21 | $104.99 |
Typical Hold Time | 43 Days | 38 Days |
Enterprise Value | -$76.33M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nano Dimension (NNDM) trades at $1.555, showing modest daily gains of 0.32%. The technical picture remains bearish with negative moving average signals, while fundamentals reveal significant challenges including a -135.18% net income margin and persistent cash burn. Recent developments include leadership changes and strategic divestitures aimed at reducing annual cash burn by $25 million, with the MarkForged sale expected to close in late 2026.
Despite trading below book value (P/B 0.68), NNDM faces substantial execution risks amid ongoing losses and negative cash flow. The company's restructuring efforts and asset sales provide potential catalysts, but investors should weigh the high-risk profile against the discounted valuation. Near-term performance hinges on successful cost reduction and revenue stabilization.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
